OPTIMIZE was a randomized, open label study, which included 330 patients with chronic kidney disease (CKD) on dialysis with hyperphosphatemia. The study was designed to evaluate different methods of ...

New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a ...

on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers a different mechanism ...

We will also present results of a survey conducted to understand why patients may be non-compliant in taking the currently prescribed phosphate binders. We look forward to contributing meaningful ...

And I'll reiterate that the need for DOs to contract for phosphate binders, including Auryxia, helped our team get to the table to contract for Vafseo at the same time. To build demand since ...

The first RIPTAC has just hit the clinic. Learn about this new technology that is being developed by Halda Therapeutics.

A growing body of research is uncovering connections between aluminium accumulation in the brain and the progression of neurodegenerative disorders such as multiple sclerosis (MS), Alzheimer's disease ...